Meet Senior Decision Makers From The Top Pharmaceutical and Biotechnology Companies In Europe

With Job Titles Including:

VPs, Directors, Heads, Senior Managers, Chiefs of ...

  • Drug Discovery
  • Research and Early Development
  • Bioinformatics
  • Computational Biology
  • Cheminformatics
  • Computational Chemistry
  • Discovery Informatics
  • Research Informatics
  • Medicinal Chemistry
  • Systems Pharmacology
  • Data Science
  • Genomics and Proteomics
  • Lead Identification and Validation
  • Translational Medicine

Solution Providers At DIA2016 Are Selected Based On The Requirements Of Our Delegates, Specialising In The Following Areas:

  • Data Analytics
  • Bio/Chem Informatics
  • Next Generation Sequencing Technology   
  • Pharmaceutical Intelligence
  • Visual Computing
  • Simulation Software
  • Text Mining Platforms
  • Image Analytics
  • Life Sciences Consultancy
  • Enterprise Technologies


John Overington

John P. Overington

Director of Biomedical Informatics and Design

Stratified Medical

Claus Bendsten

Claus Bendtsen

Director and Head of Quantitative Biology


Philippe Sanseau

Philippe Sanseau

Head of Computational Biology


Leonardo Rodrigues

Leonardo Rodrigues

Associate Director, Advanced Analytics

BERG Health

Hugo Cuelemans

Hugo Cuelemans

Head of Discovery Data Sciences Unit


Bissan Al-Lazikani

Bissan Al-Lazikani

Head of Data Science

Institute of Cancer Research

Bhushan Bonde

Bhushan Bonde

Associate Director, New Medicines IT Data Integration


Roman Affentranger

Roman Affentranger

Head of Small Molecule Discovery Workflows


Discovery Informatics & Analytics Summit 2016

Are you under pressure to reduce cycle time and drive efficiency into drug discovery and repurposing?

Following extensive consultation across global pharma and biotech organisations, the need to improve current drug discovery outcomes is a well documented business imperative. With the average drug discovery cycle taking 10 years and costing upwards of $1 billion per assay, the critical need to streamline is clear.

Have you harnessed advanced informatics and analytics to address these challenges?

With a 97% failure rate  across drug discovery, the scale of challenges in targeting, identification and compound viability  have proven considerable. With the advent of machine learning, computational biology and systems pharmacology, there is now a real opportunity to effectively accelerate the drug discovery process.

Significant improvements have already been made in drug retargeting and validation  and industry leaders are now developing the foundations for future discovery  by applying informatics & analytics principles to build data-driven decision making into the core of your discovery programme.

Why attend Discovery Informatics & Analytics 2016?

This is the only event specifically focused on how to apply advanced informatics and analytics to unlock scientific insights at discovery phase. Transformational strategies and techniques have already been applied at the forefront of discovery informatics, and this year's event will showcase practical use cases of how to power drug discovery using these tools.

Uniting senior scientists from chemistry and biology, Discovery Informatics & Analytics 2016 offers inspirational keynote speeches, practical case studies offering immediate takeaways, interactive discussion sessions, and maximum opportunity to engage and network with colleagues from Europe and beyond.

Register to attend today.



Live Streaming


Learn How To:

  • Share insight on successful profiling techniques and how they can drive drug discovery
  • Harness predictive analytics and machine learning to drive accuracy into Target Identification and Validation
  • Consider the impact of predictive modeling and improved informatics on drug repurposing and combinations
  • Learn how to overcome data standardisation challenges to advance insight capability
  • Access real use case studies to understand how to apply predictive modelling effectively
  • Address critical data sharing issues as the industry adopts pre-competitive collaboration
What The Market Is Telling Us:

"I'm very happy this is for pre-clinical data because most of the time it's about precision medicine." (Merck)

"This is seen as being an important new area we should invest in" (Eli Lilly)

"If you really want to discover something new, this more data-driven approach is valuable." (Eli Lilly)

"We are investing quite heavily in clinical datasets and trying to develop standards for easier interpretation." (Janssen)

"People are convinced there is technology out there. They just want to really know more about how it's being applied and in what way." (Sanofi)


By continuing to use this site you agree to the use of cookies. For more information and to find out how to change this click here